Senicapoc in Alzheimer's Disease
Phase 2
55
about 4.3 years
55–85
2 sites in CA
About this study
Researchers are testing Senicapoc as a treatment for Alzheimer's disease. This is a Phase II clinical trial to see if Senicapoc can help people with mild or early-stage Alzheimer's disease. It will last 52 weeks and involve measuring cognitive function, brain changes, and inflammation markers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo Tablet
- 2.Take Senicapoc
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog 13) score, Change from Baseline to Week 52 in levels of Cerebrospinal fluid (CSF) biomarkers: IL-1β, IL-6, TNF-α, MCP-1, and IL-10, Change from Baseline to Week 52 in levels of serum biomarkers: IL-6, TNF-α, MCP-1, and IL-10 and high sensitivity C-Reactive protein
Secondary: Change from Baseline in Bushcke Cued Selective Reminding Task (CSRT) score, Change from Baseline in Cognitive Event Related Potential (ERP) measures of P600 word repetition., Change from Baseline in Cognitive Event Related Potential (ERP) measures of alpha suppression effect., Change from Baseline in Cognitive Event Related Potential (ERP) measures of anti-coupling between early theta and late alpha/beta activity., Change from Baseline in Trails B score, Change from Baseline in Verbal fluency (letter) score, Change from Baseline in Verbal fluency (semantic) score, Change from Baseline in the Everyday Cognition (ECog) score
Neurology